Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Aaron S. Mansfield MD, Tobias Peikert, MD

Advertisement

Articles by Aaron S. Mansfield MD, Tobias Peikert, MD

Potential Applications of Immune Checkpoint Blockade for Mesothelioma

ByAaron S. Mansfield MD, Tobias Peikert, MD
January 28th 2015

Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.

Advertisement

Latest Updated Articles

  • Potential Applications of Immune Checkpoint Blockade for Mesothelioma
    Potential Applications of Immune Checkpoint Blockade for Mesothelioma

    January 28th 2015



Advertisement
Advertisement

Trending on OncLive

1

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

2

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

3

Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma

4

European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer

5

Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us